Skip to main content
Clinical Trials/NCT07309081
NCT07309081
Not yet recruiting
Not Applicable

Effect of Soleus Muscle Kinetic Control Training on Gait and Electromyographic Activity in Patients With Stroke

Cairo University0 sites40 target enrollmentStarted: December 15, 2025Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
40
Primary Endpoint
muscle amplitude

Overview

Brief Summary

this study was designed to investigate the effect of soleus muscle kinetic control training on Gait and electromyographic activity of the calf muscle in patients with stroke

Detailed Description

Stroke is a neurological condition characterized by a reduced blood supply to the brain tissue, resulting in paralysis of part or all of the body, limiting physical activity and social participation. Gait impairment accounts for the largest proportion of physical activity limitations in stroke patients and is characterized by muscle weakness, foot drop, spasticity, and foot deformity .Gait abnormalities following stroke are often disabling. Reduced ankle dorsiflexion, knee flexion, or hip flexion torques are often postulated causes of compromised toe clearing during the swing phase of gait. conversely, gait asymmetry and reduced walking speed has been attributed to weakness of the planter flexors.The kinetic control comprises balanced presentation of the movement choices with ideal interaction among the key components for the sensorimotor neuromuscular control that mediated by afferent sensory input, particularly the proprioceptive input, CNS integration, optimal motor co-ordination, and physiological stresses to assure functional dynamic stability and controlled mobility. forty patients with stroke will be assigned to two groups; one group will recieve kinetic control plus conventional therapy and control group will receive conventinoal therapy alone.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

opaque sealed envelope

Eligibility Criteria

Ages
45 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Ischemic or hemorrhagic stroke, as confirmed by CT and or MRI scan.
  • Age of the patients between 45 to 60 years old.
  • Ability to walk a minimum of 10 m with or without some physical assistance from a therapist (functional ambulation category more than 2).
  • Demonstrate weakness of the foot muscles, measured by muscle function tests according Medical Research council scale more than
  • Muscle tone of the affected lower limb ranges from 1 to +1 according to modified Ashworth scale.

Exclusion Criteria

  • Unilateral neglect, hemianopia, or apraxia
  • Having any other neurological disorder affecting their lower extremities e.g. MS, Parkinsonism, peripheral neuropathy.
  • Patients with previous fractures in lower limb (Ankle or foot).
  • Patients with musculoskeletal disorder such as severe arthritis, ankle surgery, leg length discrepancy or contractures of fixed deformity of ankle joint.
  • Patients with visual, auditory impairment affecting their ability to complete tasks.
  • Patients with cognitive impairments

Outcomes

Primary Outcomes

muscle amplitude

Time Frame: up to eight weeks

A steady device will be used to assess muscle amplitude in the form of RMS with microvolt as the measurement unit

stance phase percentage

Time Frame: up to eight weeks

the percentage of stance phase will be measured by steady device

giat function

Time Frame: up to eight weeks

The Dynamic Gait Index (DGI) is an ordinal test of gait function evaluates the capacity to adapt gait to complex walking tasks encountered in everyday life. Eight aspects of gait are scored based on observation as the patient walks over a 6.1-m level surface. The rater records an ordinal score that ranges from 0 (unable or done very poorly) to 3 (normal score) for a total point value of 24. Scores of less than 21 appear to suggest risk for falls

step time

Time Frame: up to eight weeks

the time of step by seconds will be measured by steady device

Gait Cycle time

Time Frame: up to eight weeks

time of gait cycle (seconds) will be measured by steady device

single and double support percentage

Time Frame: up to eight weeks

single and double support percentage of gait cycle will be measured by steady device

stride length

Time Frame: up to eight weeks

stride length by cm will be measured by steady device

swing phase percentage

Time Frame: up to eight weeks

the percentage of swing phase will be measured by steady device

cadence

Time Frame: up to eight weeks

Cadence, number of steps per minute, will be measured by steady device

first and second double support percentage

Time Frame: up to eight weeks

first and second double support percentage of gait cycle will be measured by steady devcie

gait speed

Time Frame: up to eight weeks

gait speed by km/h will measured by steady device

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Habiba Mohamed Ahmed Mahmoud

principle investigator : habiba mohamed ahmed mahmoud

Cairo University

Similar Trials